TEL AVIV, Israel, Oct. 31, 2016 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a
clinical-stage biopharmaceutical company focused on the development
of a once-daily, oral therapy for the treatment of liver diseases,
announced today that it will host a conference call and webcast on
Monday, November 7th, 2016
to discuss results for the period ended September 30, 2016 and to provide an update on
current developments with respect to its clinical programs for
Aramchol™.
Conference Call
& Webcast
|
Monday,
November 7th, 2016, 8:30 am Eastern Time / 5:30 am
Pacific Time
|
Participant Dial-In
Numbers:
|
Toll-Free:
|
+1-888-259-8885
|
Toll/International:
|
+1-913-312-1521
|
Conference
ID:
|
2611728
|
Webcast:
|
http://galmedpharma.investorroom.com/events
|
|
Replay,
available until November 21, 2016
|
Replay Dial-In
Numbers:
|
Toll-Free:
|
+1-877-870-5176
|
Toll/International:
|
+1-858-384-5517
|
Passcode:
|
2611728
|
About Galmed Pharmaceuticals Ltd.:
Galmed is a
clinical-stage biopharmaceutical company focused on the development
of a novel, once-daily, oral therapy for the treatment of liver
diseases utilizing its proprietary first-in-class family of
synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed
believes that its product candidate, Aramchol™, has
the potential to be a disease modifying treatment for fatty liver
disorders, including NASH, which is a chronic disease that Galmed
believes constitutes a large unmet medical need. Galmed is
currently conducting the ARREST Study, a multicenter, randomized,
double blind, placebo-controlled Phase IIb clinical study designed
to evaluate the efficacy and safety of Aramchol™ in
subjects with NASH, who are overweight or obese, and who are
pre-diabetic or type-II-diabetic. More information about the
ARREST Study may be found on ClinicalTrials.gov identifier:
NCT02279524.
Forward-Looking Statements:
This press release may
include forward-looking statements. Forward-looking
statements may include, but are not limited to, statements relating
to Galmed's objectives, plans and strategies, as well as
statements, other than historical facts, that address activities,
events or developments that Galmed intends, expects, projects,
believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Applicable risks and uncertainties include
risks and uncertainties associated with the initiation, timing,
progress and results of the Company's research, preclinical studies
and clinical trials as well as risks and uncertainties identified
under the heading "Risk Factors" included in Galmed's most recent
Annual Report on Form 20-F filed with the Securities and Exchange
Commission, or the SEC, on March 22,
2016, and in other filings that Galmed has made and may make
with the SEC in the future. The forward-looking statements
contained in this press release are made as of the date of this
press release and reflect Galmed's current views with respect to
future events, and Galmed does not undertake and specifically
disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Logo - http://photos.prnewswire.com/prnh/20150720/238362LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-third-quarter-2016-conference-call-and-webcast-scheduled-for-monday-november-7th-2016-300347580.html
SOURCE Galmed Pharmaceuticals Ltd.